Preliminary study: comparative effects of lung volume therapy between slow and fast deep-breathing techniques on pulmonary function, respiratory muscle strength, oxidative stress, cytokines, 6-minute walking distance, and quality of life in persons with COPD

Jirakrit Leelarungrayub1
Rungthip Puntumetakul2
Thanyaluck Sriroonreung1
Yothin Pothasak1
Jakkrit Klaphajone3

1Department of Physical Therapy, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand; 2Research Center in Back, Neck, Other Joint Pain and Human Performance (BNOJPH), Khon Kaen University, Khon Kaen, Thailand; 3Department of Rehabilitation Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

Background: Lung volume therapy with the Voldyne® device can improve lung volume and has a nonsignificant benefit on respiratory muscle strength via the slow deep-breathing technique (SDBT); whereas respiratory muscle training with a respiratory muscle trainer via the fast deep-breathing technique (FDBT) has produced a significant improvement in people with COPD. Thus, the aim of this study was to compare the efficiency of lung volume therapy with the Voldyne® device with the SDBT and FDBT on pulmonary function, respiratory muscle strength, oxidative stress, cytokines, walking capacity, and quality of life (QoL) in people with COPD.

Methods: A total of 30 COPD patient volunteers with mild (stage I) to moderate (stage II) severity were randomized into two groups: SDBT (n=15) and FDBT (n=15). Pulmonary function (FVC, FEV1, and FEV1/FVC), maximal inspiratory mouth pressure (PImax), oxidative stress status (total antioxidant capacity [TAC], glutathione [GSH], malondialdehyde [MDA], and nitric oxide [NO]), inflammatory cytokines (tumor necrosis factor-alpha [TNF-α] and IL-6), 6-minute walking distance (6MWD), and total clinical COPD questionnaire (CCQ) score were evaluated before and after 4 weeks of training. All the parameters had no statistical difference between the groups before training. The PImax, TAC, IL-6, total QoL score, and 6MWD changed significantly in the SDBT group after the 4-week experiment as compared to those in the pre-experimental period, whereas FVC, FEV1, FEV1/FVC%, PImax, TAC, MDA, NO, TNF-α, IL-6, 6MWD, and total CCQ score changed significantly in the FDBT group as compared to those in the pre-experimental period. The FEV1, %, PImax, TNF-α, IL-6, and total CCQ score differed significantly in the FDBT group in the post-experimental period as compared to those in the SDBT group.

Conclusion: This preliminary study concluded that the application of incentive spirometry with the Voldyne® device via fast deep breathing possibly improved respiratory muscle strength and QoL and reduced inflammatory cytokines, MDA, and NO better than that via slow deep breathing among people with COPD.

Keywords: COPD, cytokines, incentive spirometry, oxidative stress, 6-minute walking distance, quality of life
Introduction

COPD is currently a major and increasing health problem and will become the third most common disease leading to death worldwide, including Thailand, by 2020. Strong evidence has reported that pathophysiological changes are related to oxidative stress and inflammatory status in COPD, and endogenous oxidative stress is reportedly caused by ROS or reactive nitrogen species (RNS) generated by mitochondrial respiration and inflammatory responses to bacterial and viral infections within the lung. Both types of radicals are capable of causing oxidative damage to proteins, lipids, and DNA. Thus, a high level of lipid peroxide, malondialdehyde (MDA), or protein carbonyl and a low concentration of glutathione (GSH) or total antioxidant capacity (TAC) have been found in COPD patients and correlate significantly with disease severity or airflow obstruction. Previous reports have proposed that skeletal muscle wasting in COPD patients is related to the imbalance of oxidative stress status such as muscle atrophy and weight loss.

Previous data showed that free radicals can be produced both at rest and during muscle contraction, which involves adaptation to the regular phenomena and influence of cellular processes in exercising muscles. In addition, a low level of ROS increases force production, whereas strong increases in ROS can cause contractile dysfunction, muscle atrophy and fatigue after strenuous exercise, aging, or diseases such as COPD, cancer, and heart failure. Previous evidence found that skeletal muscle fatigue or dysfunction correlated with the diaphragm muscle in COPD. Therefore, low physical activity levels and health-related quality of life (QoL) may be limited by dyspnea. In the case of the chronic inflammatory period in COPD, strong evidence indicated that many different cells and molecules respond to the inflammatory stage, especially the release of tumor necrosis factor-alpha (TNF-α) and IL-6. Previous data showed that the release of IL-6, which may attenuate TNF-α production, was induced by exercise, especially in COPD patients. Therefore, oxidative stress and inflammation are also provoked and have a high impact on patients with COPD.

Nowadays, conventional standard treatment and rehabilitation among COPD patients have been preferred to pulmonary rehabilitation with various programs such as respiratory therapy, education programs, psychological counseling, and general exercise. Moreover, the strengthening exercise program for both general extremities and respiratory muscles has been included, which suggests more improvement in physical exercise and ability to decrease exercise-induced oxidative stress damage. Respiratory muscle training (RMT), with specific devices, has confirmed the statistical efficiency of respiratory strength and other physical performances in COPD patients. Previous evidence suggests that training for a 5- to 10-week period with an inspiratory threshold loading device could increase peak inspiratory pressure (PImax) and lung volume by FVC or FEV1, as well as improve exercise capacity, dyspnea, and QoL. Unfortunately, the high cost of the RMT device dissuades many patients living in urban areas of low-economy countries from using it. Therefore, the RMT device is not used generally worldwide. However, conventional respiratory therapy for rehabilitation is still performed without a device for breathing training or with a specific device such as that in incentive spirometry (IS), especially for increasing lung volume and ventilation. It has been reported that in the case of high-risk pulmonary atelectasis post operation, prolonged bed rest, or restrictive lung defect, application of IS has been suggested. Nowadays, IS has been divided into two types, volume-oriented (Voldyne®) and flow-oriented (Triflo II®) devices, with different recommendations for use such as 10 breaths every 1–2 hours, 10 breaths five times a day, or 15 breaths every 4 hours. However, the guideline for using both devices has recommended slow deep breathing from normal exhalation. Previous evidence showed that Voldyne® IS improved chest wall volume more than Triflo II® IS in healthy adults, especially in patients who had suffered from a stroke. Voldyne® IS also increased chest wall volume more than Triflo II® IS in elderly subjects. Interesting results from a previous study by Paiva et al showed comparison between the inspiratory muscle trainer (IMT) with a threshold IMT® and Voldyne® for 30 days among healthy females. Although training with a threshold IMT® device presented more significant increase in PImax than that with Voldyne®, Voldyne® also showed a significant PImax improvement. This result is similar to that of a previous study by Ahmadi Hosseini et al who showed that 4 weeks of IS training with the slow deep-breathing technique (SDBT) in 15 COPD patients could increase PImax significantly, which was the same as training with the RMT device. Although the use of both devices has been instructed with slow and deep breathing, the IMT® device is preferred to the IS device, with fast and forced inspiration. The question remained as to whether PImax is more significant when using the IMT® device than when using the IS device, which may be due to different instructions and whether application of the Voldyne® device, with the fast deep-breathing technique (FDBT), can improve pulmonary function, respiratory muscle strength, and six-minute walking distance (6MWD). In addition, this device still
causes oxidative stress and cytokine release among COPD patients. Previous evidence has shown that some adverse effects cause maximum sustainable voluntary ventilation to increase oxidative stress and cytokine release. This is consistent with an updated study of COPD patients performing slow-breathing yoga exercises, which increase inspiratory capacity and reduce dyspnea but do not involve oxidative stress or inflammation status. Therefore, the aim of this study was to evaluate the effects of lung volume therapy using the Voldyne® device with the FDBT and compare the outcomes with those of the SDBT.

**Methods**

**Study design and subjects**

The protocol in this study was approved by the ethics committee of the Faculty of Associated Medical Sciences, Chiang Mai University, Thailand (Study Code: AMSEC-60EX-060) and conducted in accordance with the Declaration of Helsinki (2001). The sample size of participants with COPD followed a previous study and was calculated by the G*Power program with an effect size of 0.92, alpha error of 0.05, and power of 0.95. A minimum of 14 participants in each group was required for this study. A total of 30 COPD patients, who were living at home in Sansai district, Chiang Mai, Thailand, volunteered to take part in this study. Data collection and evaluation were performed at Ban Tor-Public Health Center, Sansai district, Chiang Mai, Thailand. All the participants signed a written consent form before the program started and were then divided randomly into two groups with matching stages between mild (stage I) and moderate (stage II) severity, after the repeated pulmonary function test according to the 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD), based on the value of predicted FEV₁% and FEV₁/FVC% ratio.

Furthermore, all the participants were permitted to receive medication in the form of either a long-acting inhaled bronchodilator or long-acting inhaled steroids prescribed by a physician if needed. All of them were ex-smokers and in stable clinical condition during the experiments. If they showed uncontrolled hypertension; unstable cardiac disease; recurrent symptoms of acute exacerbation or recurrent pneumothorax, thoracic, or chest pain including neuromuscular disorders; any liver or renal dysfunction; or endocrinical abnormalities, they were excluded from this study. Any supplements or special nutrients such as multi-vitamins or N-acetylcysteine compounds were not strictly prohibited, and the basic daily activities and behavioral aspects of the participants were controlled during the 4-week experiment. Health history and QoL were investigated by interview at baseline or on the pre-experimental day, and the characteristics such as height, weight, body mass index (BMI), and blood pressure were evaluated. Blood from the anterior cubital vein was taken and kept in sterile tube containing EDTA by a medical technologist for evaluating the complete blood count (CBC) by a fully automated Olympus AU400 Analyzer (Olympus Diagnostica GmbH, Umkirch, Germany) at the AMS Clinical Service Center, Faculty of Associated Medical Sciences, Chiang Mai University, Thailand. Residual blood from a previous collection was separated in order to determine the oxidative stress markers (TAC, GSH, MDA, and nitric oxide [NO]) and inflammatory cytokines (TNF-α and IL-6). Then, repeated evaluation of the pulmonary function stage was carried out using a spirometer (HI-105; Chest M.I., Inc, Tokyo, Japan) before evaluating the respiratory muscle strength from Pimax (MicroRPM; Micro Medical Ltd., Kent, UK) and the 6MWD. All the participants were selected randomly into the SDBT or FDBT group.

**Lung volume training with Voldyne® incentive spirometry**

This study was designed in two different protocols: the SDBT and FDBT and the volume-oriented IS with the Voldyne® 5000 (Sherwood Medical, St Louis, MO). The target volume for the participants was set individually from the maximal vital capacity (VC) and pulmonary function test in the pretest period. The participants in either the SDBT or the FDBT group were instructed to take two to three cycles of normal breaths and perform maximal inspiration until the piston plate reached the target mark, and then, they tried to sustain inflation for at least 3 seconds before normal exhalation. In all, 30 breaths in three sets, with 2- to 3-minute intervals for rest, were designed to avoid possible hyperventilation or provoked dyspnea, and the rate of breathing was fixed at 20 breaths/minute. The total time for this program was twice daily, morning and evening, for 30 days. The participants performing SDBT had slow inspiration after regular exhalation, whereas those performing FDBT had fast inspiration after forced maximal exhalation. Thus, severe dyspnea from the category ratio of the Borg scale should be monitored for self-control symptoms during performance of the FDBT. During 1 month of the experiment, all the participants became educated about diseases and were permitted to carry out normal daily activities, except for regular or heavy exercise, or they practiced pursed lip breathing in cases when they felt dyspnea. Moreover, the caregivers strictly controlled the IS device by rechecking with daily telephone calls and making individual daily recordings in a logbook.
Outcome evaluation

Pulmonary function test

FVC, FEV\(_1\), and the FEV\(_1\)/FVC ratio were assessed in either liter or comparison with the predicted normal value, which was evaluated from the FVC maneuver in pulmonary function test. All the participants were required to wear a nose clip while sitting on a chair with a back for support. Careful instructions and coaching were given to prevent air leaks from around the flange of the mouthpiece. Three cycles of slow normal breaths were taken before performing maximal inhalation and exhalation and returning to normal breath. All data were printed after the test was completed. The highest liter value of FEV\(_1\) and FVC was selected finally from three repeated measurements in not more than eight tests.

Respiratory muscle strength test

Respiratory muscle strength was evaluated by measuring the maximal inspiratory mouth pressure (MIP or PI\(_{\text{max}}\)) at residual volume in sitting position by using a portable handheld mouth pressure meter (MicroRPM). All the participants were seated with nose clips on, and the flange of the mouthpiece was used in order to prevent air leaks, as required. A sharp, forceful effort was maintained in each test for a minimum of 3–4 seconds. Furthermore, the interval for rest between each effort was 1–3 minutes or more if dyspnea symptoms were present. The highest data output in units of centimeter water (cmH\(_2\)O) from three repeated efforts or a drop of more than 20% from the previous effort was the criterion for stopping the procedure.

Oxidative stress and cytokine evaluation

Whole blood of 400 µL was taken from residual blood to evaluate the GSH by 5,5'-dithiobis-2-nitrobenzoic acid (DTNB) reagent, and the residual blood was used to separate plasma by centrifugation at 3,000x g for 10 minutes. Fresh plasma was used to evaluate the TAC by 2,2'-dithiobis(2-nitrobenzoic acid) (DTNB) reagent, and NO by Griess reagent. Other plasma was frozen for determining the inflammatory cytokines (TNF-\(\alpha\) and IL-6) using human ELISA kits (Quantikine\(\alpha\); R&D systems, Inc., Minneapolis, MN) and MDA by thiobarbituric acid (TBA) reactive substances. All the parameters were evaluated experimentally at the Biomechanics Laboratory of the Department of Physical Therapy, Faculty of Associated Medical Sciences, Chiang Mai University, Thailand.

6MWD test

The 6MWD test was evaluated by following the guideline of the 2002 ATS. A modified protocol of the 20-meter straight walking test, with turn around points marked at the end by colored tape, was performed in an indoor corridor. Any vigorous activities and eating 2 hours before the test were avoided. Comfortable clothes and shoes could be worn during the test, and vital signs such as respiratory rate, oxygen saturation, heart rate, and blood pressure were evaluated before and after it for safety reasons. The participants were instructed to walk at a comfortable pace for 6 minutes under the supervision of a physiotherapist and allowed to stop and rest during the test if feeling strong or heavy dyspnea (equal to 6 from the maximal 10 of the Borg scale), in accordance with the guideline of the American College Society of Medicine (ACSM).

QoL evaluation

QoL was assessed using the Clinical COPD Questionnaire (CCQ), which consisted of 10 questions in three domains: four items of symptoms, two items of mental state, and four items of functional state. The questions were asked 1 week before starting the test or before the experiments in this study, and the 7-point score from 0 to 6 was used. The CCQ held the total score in the main measurement of outcome, calculated as the mean sum of all items, whereas each item was calculated with the highest value presenting the worst health status and the lowest value presenting the best one.

During 4 weeks of training, a self-reporting logbook was kept and rechecked by the caregivers, as well as reverified every 2 weeks of the experiment by a physical therapist using phone calls and personal appointments at Ban Tor-Public Health Center.

Statistical analyses

All the data were analyzed statistically for normal distribution using the one-sample Kolomogorov–Smirnov test before presenting as mean, with SD, and minimal and maximal values. The characteristics between the two groups were analyzed by the independent \(t\)-test. The data of pulmonary function, PI\(_{\text{max}}\), oxidative stress parameters, cytokines, QoL, and 6MWD between the groups before and after 4 weeks of training were analyzed by two-way ANOVA measurement (two groups and two times). All statistical analyses were carried out using the SPSS software version 17.0 (SPSS Inc., Chicago, IL, USA) for Windows. All the tests were used with significance at a \(P\)-value of <0.05. Moreover, the effect size from the results within a group with a Cohen value (\(d\)) was analyzed by the...
Power program 3.1.9.2, which showed three levels: small ($d=0.2$), moderate ($d=0.5$), and large ($d>0.8$). Therefore, the moderate to large effect size and the results of significant value indicated credible statistical analysis despite the small sample size in this study.  

**Results**

**Characteristic results**

The results of CBC in all the participants were within the reference value in the pre-experimental period (data not shown). The two groups were well matched regarding age, weight, height, BMI, and blood pressure, with no significant difference between them (Table 1). All the parameters (FVC, FEV$\_1$, FEV$\_1$/FVC ratio, PI$\_\text{max}$, 6MWD, and total CCQ), all oxidative stress markers (TAC, GSH, NO, MDA, and cytokines), TNF-$\alpha$, and IL-6 were not statistically different at the baseline data in either group ($P>0.05$; Figures 1–3). In addition, all the data showed normal distribution due to nonsignificant results from the one-sample Kolmogorov–Smirnov test ($P>0.05$). Therefore, the data were expressed as mean and SD.

**Pulmonary function and respiratory muscle strength results**

There were no statistical changes in any lung functions in the SDBT group, whereas FVC (L; $P=0.001$), FEV$\_1$ (L; $P=0.000$), and FEV$\_1$/FVC% ($P=0.000$) changed significantly in the FDBT group (Figure 1A–C) with a large effect size ($d=1.0, d=1.15$, and $d=1.39$), and the FEV$\_1$/FVC% ($P=0.036$; Figure 1D) had a moderate effect size ($d=0.59$; Table 2). The FVC (L), FEV$\_1$ (L), and FEV$\_1$/FVC% were not significantly different between the groups in the post-training period, except for the result of FEV$\_1$/FVC% ($P=0.017$). Regarding results for respiratory muscle, both training groups showed a significant increase in PI$\_\text{max}$, SDBT, $P=0.01$ and $d=0.76$, and FDBT, $P=0.001$ and $d=1.15$. PI$\_\text{max}$ in the FDBT group was significantly higher than that in the SDBT group when compared with the post-training period ($P=0.019$; Table 2 and Figure 1E).

**Oxidative stress and inflammatory cytokine results**

There was no significant change in the GSH level in either group between the pre- and post-training periods. TAC significantly increased in both training techniques: SDBT, $P=0.002$ and FDBT, $P=0.000$ (Figure 2A), with a large effect size ($d=0.99$ and $d=1.91$, respectively; Table 3), but with no significant difference ($P=0.237$) between the groups in the post-training period. MDA and NO reduced significantly in only the FDBT group ($P=0.005$ and $P=0.005$, respectively; Figure 2B and C) with a large effect size ($d=0.85$ and $d=2.60$, respectively; Table 3), but there was no significant difference from those of the SDBT group. The result of TNF-$\alpha$ showed a significant change in the FDBT group ($P=0.000$; Figure 2D) with a large effect size ($d=2.01$; Table 3), whereas no change occurred in the SDBT group ($P=0.059$). Both groups showed a significant reduction in IL-6 levels ($P=0.024$ and $P=0.000$; Figure 2E) with a moderate effect size ($d=0.68$) and large effect size ($d=2.08$, respectively; Table 3). In addition, the IL-6 level in the post-training period was significantly lower in the FDBT group than in the SDBT group ($P=0.017$).

**6MWD and QoL results**

After 4 weeks of training, the 6MWD significantly increased in both groups ($P=0.034$ and $P=0.000$; Figure 3A) with a moderate effect size ($d=0.63$) and large effect size ($d=1.87$) in the SDBT group and FDBD group (Table 4), respectively.

---

**Table 1 Characteristics of all the participants in the SDBT and FDBT groups**

<table>
<thead>
<tr>
<th>Variables</th>
<th>SDBT (n=15)</th>
<th>FDBT (n=15)</th>
<th>$P$-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>70.1±9.57 (51–91)</td>
<td>73.27±10.48 (46–84)</td>
<td>0.41</td>
</tr>
<tr>
<td>Sex, M:F</td>
<td>4:11</td>
<td>3:12</td>
<td>–</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>53.9±11.43 (36.2–69.2)</td>
<td>59.25±14.07 (36.4–81.2)</td>
<td>0.27</td>
</tr>
<tr>
<td>Height (m)</td>
<td>1.54±0.02 (1.40–1.65)</td>
<td>1.59±0.09 (1.40–1.70)</td>
<td>0.15</td>
</tr>
<tr>
<td>BMI (kg/m$^2$)</td>
<td>22.56±4.63 (16.22–30.73)</td>
<td>23.02±3.88 (17.63–29.27)</td>
<td>0.77</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>121.7±13.46 (110–132)</td>
<td>120.2±4.4 (100–132)</td>
<td>0.65</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>72.86±10.78 (56–89)</td>
<td>88.4±9.12 (65–98)</td>
<td>0.42</td>
</tr>
<tr>
<td>Bronchodilators</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sereide$^®$ (MDI)</td>
<td>9</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Berodual$^®$ (MDI)</td>
<td>4</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** Data are presented as number or mean and SD (minimal and maximal value). $P$-value was analyzed by the independent pair t-test. The “–” indicates no statistical analysis.

**Abbreviations:** SDBT, slow deep-breathing technique; FDBT, fast deep-breathing technique; M, male; F, female; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; MDI, metered-dose inhaler.
but there was no significant difference between the two groups in the post-training period \((P=0.269)\). Regarding results for QoL, both techniques reduced the total QoL score significantly when compared with that of pre-training \((P=0.003 \text{ and } P=0.001; \text{Figure 3B})\) with a large effect size \((d=0.97 \text{ and } d=1.10)\), as well as reduced the sub-item symptom score \((P=0.028 \text{ and } P=0.001)\) with a moderate effect size \((d=0.66)\) and large effect size \((d=1.07)\) in the SDBT.
and FDBT groups (Table 4), respectively. The FDBT group showed a reduction in sub-item mental and function scores ($P=0.045$ and $P=0.026$) with a large effect size ($d=1.13$) and moderate effect size ($d=0.62$), but there were no significant changes in the SDBT group. When comparing between the groups in the post-training period, the scores of total CCQ, symptom, and function were significantly different ($P=0.021$, $P=0.017$, and $P=0.08$, respectively; Table 4).
Discussion

The results of this study offer a preliminary presentation of the different effects of instruction for IS application between the SDBT and FDBT. Previous recommendations of IS application can improve lung volume by slow deep inspiration from functional residual capacity (FRC) or at the end of regular exhalation according to the American Association for Respiratory Care (AARC) Clinical Practice Guideline.24 It has been proposed that the clinical benefit of IS improves lung volume and prevents atelectasis in various conditions such as post coronary artery bypass grafting (CABG).24 The Voldyne® device, which is classified as volume-oriented IS, seems to have more benefits than flow-oriented IS such as the Triflo® II device.25 Previous data reported that the Voldyne® device improved chest wall volume in healthy adults,26 elderly subjects,27 and patients with stroke.28 In 2015, the study of Paiva et al29 showed that the Voldyne® device can be applied for training the strength of respiratory muscles in healthy females25 and COPD patients.30 $\text{PI}_{\text{max}}$ is the principle parameter of respiratory muscle strength, and it must be evaluated and increased after application. Unfortunately, increasing $\text{PI}_{\text{max}}$ after applying the Voldyne® device was not similar to training with a threshold IMT® device. Therefore, different instructions may be provided for IS and threshold IMT® devices.32 All the participants in this study were instructed to take two to three cycles of normal breaths before slow or fast deep inspiration or breathing from residual volume in 30 continuous breaths. Rest intervals of 2–3 minutes were permitted in each cycle of 10 breaths, at the slow rate of 20 breaths per minute, for preventing dyspnea symptoms. The visual target for maximal effort in all the participants was at the maximal volume in the piston plate marked beside the Voldyne® device, which had been fixed closely in order to equal the maximal VC from the pulmonary function test in the pre-experimental period.

Although the number of participants with COPD was small in this study (15 in each group), it may be enough for statistical results, as a previous study was carried out with 13 COPD patients.29 Furthermore, Heydari et al30 also had 30 COPD patients divided into two groups (n=15) to study the efficiency of inspiratory-resistive muscle training using incentive spirometry within 4 weeks of training.

The main parameters were $\text{PI}_{\text{max}}$, which indicated the respiratory muscle strength and pulmonary function; FVC; FEV$_1$; and FEV$_1$/FVC in either liter or percentage of the predicted values. The results showed that both the SDBT and FDBT increased $\text{PI}_{\text{max}}$ significantly, with a large effect size, but $\text{PI}_{\text{max}}$ increased more with the FDBT than with the SDBT. Although the mechanism of the FDBT improves $\text{PI}_{\text{max}}$ better than the SDBT, this is still unclear. However, the high forcing technique in the FDBT is the same as that performed in the RMT device and is possibly expected to induce respiratory muscle strength quickly. Regarding results of the lung function, the SDBT did not improve any of the pulmonary parameters, whereas the FDBT improved them significantly, except for FVC%. When comparing the data between the two tests in the post-experimental period, the FEV$_1$% showed a significant difference. Thus, the FDBT did not affect any of the pulmonary function parameters, except FEV$_1$%. These results are similar to those in a previous study in 2015 by Heydari et al,30 who compared incentive spirometry with the inspiratory muscle training program.
Table 2 Pulmonary function test and respiratory muscle strength in both groups before and after training

<table>
<thead>
<tr>
<th>Parameters</th>
<th>SDBT (n=15) Before</th>
<th>SDBT (n=15) After</th>
<th>P-value</th>
<th>d</th>
<th>FDBT (n=15) Before</th>
<th>FDBT (n=15) After</th>
<th>P-value</th>
<th>d</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary function</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FVC (L)</td>
<td>2.05±0.65 (0.60–2.99)</td>
<td>2.17±0.78 (0.77–3.52)</td>
<td>0.90</td>
<td>0.47</td>
<td>2.29±0.69 (1.21–4.25)</td>
<td>2.50±0.70 (1.17–4.12)</td>
<td>0.001</td>
<td>1.0</td>
</tr>
<tr>
<td>FVC (%)</td>
<td>91.23±13.41 (71.43–113.16)</td>
<td>93.72±21.00 (62.25–125.25)</td>
<td>0.56</td>
<td>0.16</td>
<td>97.41±9.04 (82.01–115.22)</td>
<td>99.43±16.28 (52.00–120.12)</td>
<td>0.577</td>
<td>0.15</td>
</tr>
<tr>
<td>FEV₁ (L)</td>
<td>1.30±0.59 (0.31–2.37)</td>
<td>1.41±0.56 (0.51–2.36)</td>
<td>0.18</td>
<td>0.74</td>
<td>1.56±0.59 (0.73–3.38)</td>
<td>1.81±0.64 (0.77–3.43)</td>
<td>0.000</td>
<td>1.15</td>
</tr>
<tr>
<td>FEV₁ (%)</td>
<td>62.00±11.92 (50.00–79.21)</td>
<td>62.84±10.73 (51.16–79.23)</td>
<td>0.63</td>
<td>0.13</td>
<td>68.02±6.62 (56.34–79.50)</td>
<td>71.62±7.02 (61.23–84.00)</td>
<td>0.000</td>
<td>1.39</td>
</tr>
<tr>
<td>FEV₁/FVC (%)</td>
<td>66.38±3.94 (59.56–70.00)</td>
<td>66.96±6.94 (56.49–78.45)</td>
<td>0.71</td>
<td>0.10</td>
<td>67.48±2.68 (62.00–70.00)</td>
<td>70.68±4.71 (62.00–83.25)</td>
<td>0.036</td>
<td>0.59</td>
</tr>
<tr>
<td>PI_max (cmH₂O)</td>
<td>63.35±24.21 (25–102)</td>
<td>69.78±21.23 (39–105)</td>
<td>0.01</td>
<td>0.76</td>
<td>64.13±20.59 (42–124)</td>
<td>91.64±42.15 (64–135)</td>
<td>0.001</td>
<td>1.15</td>
</tr>
</tbody>
</table>

Notes: The data are mean±SD (min–max). P-value and d effect size value from statistical analysis were compared to those in the pre-experimental period in each group. *P-value from statistical analysis between the two groups in the post-experimental period.

Abbreviations: SDBT, slow deep-breathing technique; FDBT, fast deep-breathing technique; PI_max, maximal inspiratory pressure.

Table 3 Oxidative stress markers (TAC, GSH, MDA, and NO) and cytokine markers (TNF-α and IL-6) in both groups before and after the experimental period

<table>
<thead>
<tr>
<th>Parameters</th>
<th>SDBT (n=15) Before</th>
<th>SDBT (n=15) After</th>
<th>P-value</th>
<th>d</th>
<th>FDBT (n=15) Before</th>
<th>FDBT (n=15) After</th>
<th>P-value</th>
<th>d</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxidative stress marker</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TAC (mmol Trolx/L)</td>
<td>1.10±0.04 (1.04–1.17)</td>
<td>1.16±0.07 (1.00–1.25)</td>
<td>0.002</td>
<td>0.99</td>
<td>1.10±0.06 (1.01–1.24)</td>
<td>1.18±0.06 (1.10–1.31)</td>
<td>0.000</td>
<td>1.91</td>
</tr>
<tr>
<td>GSH (mg/dL)</td>
<td>62.79±7.98 (50.66–82.21)</td>
<td>59.84±1.61 (48.30–80.50)</td>
<td>0.215</td>
<td>0.35</td>
<td>64.41±3.61 (58.37–68.92)</td>
<td>61.33±10.42 (40.61–73.37)</td>
<td>0.250</td>
<td>0.36</td>
</tr>
<tr>
<td>MDA (µmol/L)</td>
<td>7.24±3.49 (2.99–14.96)</td>
<td>5.92±2.92 (2.40–13.09)</td>
<td>0.206</td>
<td>0.36</td>
<td>7.47±2.11 (5.11–12.34)</td>
<td>5.46±1.52 (3.00–7.68)</td>
<td>0.005</td>
<td>0.85</td>
</tr>
<tr>
<td>NO (µmol/L)</td>
<td>5.94±5.00 (2.20–20.35)</td>
<td>4.16±1.85 (2.33–7.97)</td>
<td>0.084</td>
<td>0.50</td>
<td>5.90±2.95 (3.00–14.20)</td>
<td>4.02±2.12 (1.50–8.01)</td>
<td>0.005</td>
<td>2.60</td>
</tr>
<tr>
<td>Cytokine marker</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNF-α (pg/mL)</td>
<td>11.95±3.70 (6.4–17.6)</td>
<td>10.89±3.35 (6.8–16.51)</td>
<td>0.059</td>
<td>0.55</td>
<td>10.95±3.36 (7.5–17.5)</td>
<td>6.72±1.88 (4.5–10.5)</td>
<td>0.000</td>
<td>2.01</td>
</tr>
<tr>
<td>IL-6 (pg/mL)</td>
<td>8.71±3.98 (3.4–15.4)</td>
<td>7.68±3.24 (3.5–13.5)</td>
<td>0.024</td>
<td>0.68</td>
<td>9.62±3.63 (4.2–15.6)</td>
<td>5.09±2.17 (2.6–8.5)</td>
<td>0.000</td>
<td>2.08</td>
</tr>
</tbody>
</table>

Notes: The data are mean±SD (min–max). P-value and d effect size value from statistical analysis were compared to those in the pre-experimental period in each group. *P-value from statistical analysis between the two groups in the post-experimental period.

Abbreviations: TAC, total antioxidant capacity; GSH, glutathione; MDA, malondialdehyde; NO, nitric oxide; TNF-α, tumor necrosis factor alpha; SDBT, slow deep-breathing technique; FDBT, fast deep-breathing technique.
Table 4 6MWD and QoL in both groups before and after the experimental period

<table>
<thead>
<tr>
<th>Parameter</th>
<th>SDBT (n=15)</th>
<th>FDBT (n=15)</th>
<th>P-value</th>
<th>d</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before</td>
<td>After</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>303.14±121.01 (110–495)</td>
<td>324.50±108.66 (121–523)</td>
<td>0.034</td>
<td>0.63</td>
<td></td>
</tr>
<tr>
<td>6MWD (m)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>QoL Total score</td>
<td>1.41±0.91 (0.20–2.80)</td>
<td>0.99±0.69 (0.00–2.20)</td>
<td>0.003</td>
<td>0.97</td>
<td>0.99±0.75 (0.00–2.75)</td>
</tr>
<tr>
<td>Symptom</td>
<td>2.27±1.34 (0.50–4.25)</td>
<td>1.74±1.13 (0.00–3.75)</td>
<td>0.028</td>
<td>0.66</td>
<td>1.72±1.15 (0.00–4.35)</td>
</tr>
<tr>
<td>Mental</td>
<td>0.43±0.55 (0.00–1.50)</td>
<td>0.46±0.66 (0.00–2.00)</td>
<td>0.836</td>
<td>0.06</td>
<td>0.40±0.60 (0.00–2.00)</td>
</tr>
<tr>
<td>Function</td>
<td>1.04±1.13 (0.00–3.50)</td>
<td>0.80±0.89 (0.00–2.50)</td>
<td>0.240</td>
<td>0.32</td>
<td>0.91±0.65 (0.00–2.75)</td>
</tr>
</tbody>
</table>

Notes: The data are mean±SD (min–max). P-value and d effect size value from statistical analysis were compared to those in the pre-experimental period in each group. *P-value from statistical analysis between the two groups in the post-experimental period.

Abbreviations: 6MWD, 6-minute walking distance; QoL, quality of life; SDBT, slow deep-breathing technique; FDBT, fast deep-breathing technique.
period. However, the improvement of MDA and NO from the FDBT is very interesting and should be studied further. A previous study in hemodialysis patients showed that RMT did not affect the MDA level; thus, some mechanisms may reduce MDA and NO production. Interesting results of MDA and NO levels, when applied to the FDBT, significantly reduced both parameters with possible clinical benefits because high NO and MDA are related to disease severity and airflow obstruction. Therefore, reduction of NO and MDA in this study possibly helped to prevent exacerbation of the disease. Furthermore, the result of significant TNF-α reduction in the FDBT and IL-6 in both groups is also very interesting and cannot be explained. However, some evidence reported that the signaling pathway of TNF-α release is sensitive to ROS. Moreover, IL-6 has been claimed to affect airway limitation and emphysema progression. Thus, reduction of plasma IL-6 in this study possibly delays the disease progression in the clinic. However, further study on the mechanisms involved in changes in both cytokines by the FDBT is still needed. Previous evidence reported that these cytokines did not respond to either the high or low intensity of IMT in patients with chronic heart failure for 10 weeks. However, this study was performed with COPD patients who had a different condition. Therefore, a study of the FDBT on oxidative stress and cytokine release, especially antioxidant enzymes or the signaling pathway on cytokine release, should be carried out.

In addition, the clinical efficiency from both techniques has been studied with 6-minute walking capacity and QoL. The 6MWD provides information regarding functional capacity and response to training. Previous evidence suggested that a distance of <350 m is associated with a higher mortality in COPD patients, and previous data claimed that the clinically important difference for 6MWD should be 53 m. Therefore, IS application in the FDBT increased the 6MWD from 307.87±70.41 m to 362±67.58 m, which indicated a clinically significant improvement as compared to that in the SDBT (303.14±121.01 m–324.50±108.66 m). Dominant response to the 6MWD in the FDBT group is suggested that a distance of 350 m is associated with a higher mortality in COPD patients, and previous data claimed that the clinically important difference for 6MWD should be 53 m. Therefore, IS application in the FDBT increased the 6MWD from 307.87±70.41 m to 362±67.58 m, which indicated a clinically significant improvement as compared to that in the SDBT (303.14±121.01 m–324.50±108.66 m). Dominant response to the 6MWD in the FDBT group is related possibly to the results of $P_{\text{max}}$, oxidative stress, and cytokines, when compared with SDBT results. This hypothesis can be believed because of a previous study that found association between the 6MWD and inspiratory VC. Therefore, increased 6MWD may be the result of increased $P_{\text{max}}$ data. Finally, the QoL confirmed efficiency of the training, and both groups had a significantly decreased score that showed improvement in QoL. The CCQ was used in this study because of its short items and time-saving interview, with only 10 items consisting of symptom, mental state and functional state. Previous evidence showed that the CCQ significantly correlated with the St George’s Respiratory Questionnaire (SGRQ), COPD assessment (CAT), and modified Medical Research Council scale. The results showed improvement in the total CCQ score, which was the same as that in the sub-item symptom score. The mental score was not significantly different in either group. However, the sub-item function score showed a significant improvement in the FDBT group. Moreover, the total CCQ score, symptoms, and function in the FDBT group were significantly different to those in the SDBT group in the post-experimental period. Therefore, significant changes possibly correlate with FEV$_1$/FVC, $P_{\text{max}}$, oxidative stress, and cytokines.

**Clinical application and limitations**
This preliminary study design did not include control participants, but they might not have been necessary as the COPD patients were in a stable condition. Berodual® and Seretide™ bronchodilators were used in both groups depending on occasional symptom aggravation. The influence of medications during lung volume therapy may have impacted the results, thus, should be studied in the future. In addition, this study aimed to show the clinical benefits of lung volume therapy with the Voldyne® device between slow and fast deep breathing. Therefore, the significant difference between the two groups was enough. The fast deep-breathing protocol twice daily for 30 days in the COPD patients had more clinical benefits in FEV$_1$, $P_{\text{max}}$, QoL, and walking distance than the slow deep-breathing protocol. Instruction of IS with fast, quick, and deep breathing maneuver, as in the RMT protocol, can be applied in the clinic. Improvement of $P_{\text{max}}$ and FEV$_1$ is very challenging when compared with the conventional SDBT. However, most of the participants in this study were classified as stage II (moderate severity), and the low sample size with mixed females and males was a limitation. Application of IS with FDBT to other stages such as severe COPD or patients diagnosed with predominant emphysema is also not predicted. Future research regarding the study of COPD patients, with a larger sample size, varied severity, and combination medications, is still needed for possible application in various conditions.

**Conclusion**
This preliminary study of patients with COPD can conclude that application of incentive spirometry with the Voldyne® device via fast deep breathing seems to improve respiratory muscle strength and QoL and reduce inflammatory cytokines, MDA, and NO better than that via slow deep breathing.
Acknowledgments

This study was given a grant from the Research Center in Back, Neck, Other Joint Pain and Human Performance (BNOJP), Khon Kaen University, Khon Kaen, Thailand. The authors thank all the participants and caregivers for their assistance in helping to control and organize the training with good consistency. Thanks also go to all the physical therapists at Sansai Hospital, Chiang Mai, who organized space for collecting data.

Disclosure

The authors report no conflicts of interest in this work.

References

42. Leelarungrayub J, Laskin JJ, Bloomer RJ, Pinkaew D. Consumption of star fruit juice on pro-inflammatory markers and walking distance in the community dwelling elderly. *Arch Gerontol Geriatr.* 2016;64:6–12.